Term ends Oct 20, 2030 · Low confidence
20-year base term ends Oct 20, 2030
Held by Revance Therapeutics, Inc.
Filed Dec 2, 2019 as application 16/700,728 · Granted Oct 11, 2022
Base term, 20 years from filing
Today
2010
2030
Clock starts
Oct 20, 2010
Oct 20, 2010
Term ends
Oct 20, 2030
Oct 20, 2030
Granted
Oct 11, 2022
Oct 11, 2022
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,469,849, to Oct 20, 2030. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 20, 2010, when application PCT/US2010/053389, the earliest non-provisional in its chain, was filed (this one was filed Dec 2, 2019); a parent in its chain could not be resolved (the next row) | Oct 20, 2030 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,469,849) | resolves to Oct 20, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 15295134, 14796235 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Oct 20, 2030 | Low confidence |
This family
| Application 61/253,810 | Provisional application no patent term | no patent term |
| Application PCT/US2010/053389 | PCT application no patent term | no patent term |
| Application 13/394,506 | Abandoned not computed | not computed |
| US 9,469,849 | In force Oct 2030 | Oct 2030 |
| Application 15/295,134 | Abandoned not computed | not computed |
| US 11,466,262 | this patent Oct 2030 | Oct 2030 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2030
Term ends Oct 20, 2030. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,469,849, ends no earlier than this term, so it caps nothing.
Citations
9
later US patents cite this one
That is top 25% of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.